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APOBEC3F Properties and Hypermutation Preferences
Indicate Activity against HIV-1 In Vivo
also that the two might share a common mode of regu-
lation.
To investigate whether APOBEC3F was capable of
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University of Minnesota
Department of Biochemistry, Molecular Biology, restricting retroviral infection, we produced HIV-1-
based retroviruses encoding green fluorescent proteinand Biophysics
321 Church St. S.E. (HIV-GFP) with 293T cells expressing APOBEC3F, APO-
BEC3G, or an empty vector. We normalized these stocks6-155 Jackson Hall
Minneapolis, Minnesota 55455 and used them to infect fresh 293T target cells. After
2 days, infectivity was monitored by flow-cytometric
detection of GFP fluorescence. HIV-GFP produced in
the presence of either APOBEC3F or APOBEC3G showed
Summary 3.2- and 9.6-fold decreases in infectivity, respectively
(Figure 1A). Production of HIV-GFP in the presence of
APOBEC3G (CEM15 [1]) deaminates cytosine to uracil 4-fold more APOBEC3F or APOBEC3G resulted in even
in nascent retroviral cDNA [2–5]. The potency of this larger decreases (Figure 1B). APOBEC3F and APO-
cellular defense is evidenced by a dramatic reduction BEC3G also restricted a murine leukemia virus (MLV)-
in viral infectivity and the occurrence of high frequen- based retrovirus, MLV-GFP [2] (Figure 1B). Thus, like
cies of retroviral genomic-strand G→ A transition mu- APOBEC3G, APOBEC3F is clearly a potent and likely a
tations [2–5]. The overwhelming dinucleotide hyper- broad restrictor of retroviral infection.
mutation preference of APOBEC3G acting upon a We asked whether APOBEC3G could influence the
variety of model retroviral substrates is 5-GG → -AG restrictive phenotype caused by APOBEC3F because
[2–4, 6–8]. However, a distinct 5-GA→ -AA bias, which high levels of similarity suggested that these two pro-
is difficult to attribute to APOBEC3G alone [9], prevails teins might associate with each other (self-interaction
in HIV-1 sequences derived from infected individuals has been shown for some APOBEC family members,
(e.g., [10]). Here, we show that APOBEC3F is also a including APOBEC3G [8, 11, 12]). To begin to address
potent retroviral restrictor but that its activity, unlike this, we produced viruses with cells expressing both
that of APOBEC3G, is partially resistant to HIV-1 Vif APOBEC3F and APOBEC3G. Interestingly, intermediate
and results in a clear 5-GA→ -AA retroviral hypermu- declines in retroviral infectivity were observed in com-
tation preference. This bias is also apparent in a bacte- parison to those caused by APOBEC3F or APOBEC3G
rial mutation assay, suggesting that it is an intrinsic alone (Figures 1A and 1B). These data implied that the
APOBEC3F property. Moreover, APOBEC3F and APO- reductions in infectivity were additive.
BEC3G appear to be coordinately expressed in a wide To confirm this possibility and to compare their rela-
range of human tissues and are independently able to tive potencies, we titrated APOBEC3F and APOBEC3G
inhibit retroviral infection. Thus, APOBEC3F and APO- into viral producer cells and monitored the resulting
BEC3G are likely to function alongside one another infectivities. Less APOBEC3G appeared necessary to
in the provision of an innate immune defense, with trigger a drop in infectivity, suggesting that it might be
APOBEC3F functioning as the major contributor to slightly more potent (Figure 1C). Second, we took advan-
HIV-1 hypermutation in vivo. tage of the fact that an established amount of either
APOBEC3F or APOBEC3G could cause a predictable
decline in retroviral infectivity; this amount was bestResults and Discussion
described as a percent lethal dose (LD%). Viruses were
produced in the presence of an LD50 of APOBEC3F andDuring a comparison of APOBEC3G (apolipoprotein B
increasing amounts of APOBEC3G. For concentrationsmRNA-editing enzyme catalytic polypeptide-like protein
at which APOBEC3G had a clear effect, the infectivity3G) and its human homologs, we were struck by the
decrease added to that attributable to APOBEC3F (Fig-remarkable conservation of the N termini of APOBEC3G
ure 1C). These experiments indicated that APOBEC3Fand APOBEC3F, in which 59/60 amino acids are identi-
and APOBEC3G were capable of independently re-cal (Figure S1 in the Supplemental Data available with
stricting retroviral infectivity, even when coexpressed.this article online; also see [11]). Similarity also extends
To ascertain whether APOBEC3F restricted retroviralthrough the C termini, yielding 65% overall. The two
infection by a cDNA deamination mechanism or by angenes are positioned adjacent to one another on human
alternative mode as proposed recently for APOBEC3Gchromosome 22, show largely conserved exon bound-
and the hepatitis B virus [13], we analyzed retroviralaries, and—remarkably—share more than 90% identity
DNA sequences amplified from 293T cells infected within the 5000 bp promoter regions upstream of the transla-
viruses produced in the presence of APOBEC3F, APO-tion start codons (97% in the first 850 bp). These strong
BEC3G, APOBEC3F plus APOBEC3G, or a vector con-similarities indicated not only that APOBEC3F might
trol. APOBEC3F triggered a 14-fold increase in HIV-GFPpossess an APOBEC3G-like antiretroviral activity but
plus-strand G→A transitions, with up to a dozen individ-
ual mutations occurring per 747 bp interval analyzed
(Figures 2A–2C). APOBEC3G also caused G→ A transi-*Correspondence: rsh@umn.edu
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dues during retroviral reverse transcription, by a mecha-
nism analogous to that used by APOBEC3G.
A closer inspection of the APOBEC3F hypermutation
hotspots revealed a strong bias for adenine immediately
3 of the mutated plus-strand guanine (5-GA), in con-
trast to APOBEC3G, which preferred 5-GG (Figure 2A;
[2]). The three hottest 5-GA dinucleotide sites, G339, G363,
and G492, accounted for 24% (44/184) of the APOBEC3F-
dependent hypermutations. In contrast, out of 104 G→A
transitions reported here and 734 reported previously
for APOBEC3G [2], the same sites harbored only 1.9%
of the hypermutations (2/104 plus 14/734). In total, 70%
and 87% of the APOBEC3F- and APOBEC3G-preferred
dinucleotides were 5-GA and -GG, respectively. We
noted also that approximately one-fifth of the APO-
BEC3F-triggered events were 5-GC → -AC (minus-
strand GC → GT). These coincided with a notable level
of plus-strand C→ T transitions (14/24 were GC→ GT).
These apparently minor preferences may be attributable
to APOBEC3F eliciting a secondary activity that enables
deamination of plus-strand cytosines or, more likely,
deamination of single-stranded retroviral genomic RNA.
It may also simply be a consequence of APOBEC3F
overexpression. Nevertheless, the major dinucleotide
preferences of APOBEC3F and APOBEC3G are clearly
distinct: 5-GA and -GG, respectively.
Interestingly, retroviral DNA derived from cells coex-
pressing APOBEC3F and APOBEC3G showed clear ex-
amples of 5-GA and -GG hypermutation within the same
sequence (as often observed in vivo, e.g., [10]), and
they also showed higher-than-expected hypermutation
frequencies (Figures 2 and S2). Because coexpression
experiments used equivalent amounts of APOBEC3F
and APOBEC3G (in each case, half that used in single
APOBEC experiments) and produced additive infectivity
declines (Figure 1), we expected additive increases in
mutation frequency. Instead, APOBEC3F and APOBEC3G
coexpression more than doubled the expected hyper-
mutation frequency (Figure 2; A3F and A3G [226/
Figure 1. APOBEC3F Restricts Retroviral Infection
34,303]  A3F [(184/88,864)/2]  A3G [(104/36,741)/2].
(A) A representative experiment showing the reduced infectivity of
This difference was even greater when sequences har-HIV-GFP produced in the presence of APOBEC3F (A3F), APOBEC3G
boring only G→A hypermutations were considered (also(A3G), or APOBEC3F plus APOBEC3G. The percentage of fluoresc-
see Figure S2).ing infected target 293T cells is indicated. Each dot represents one
cell. A number of factors are likely to influence the selection
(B) Histograms showing the relative retroviral-infectivity decreases of retroviral minus-strand cytosines for APOBEC-depen-
caused by APOBEC protein expression. Infectivity in the absence dent deamination. Additional factors are likely to influ-
of any APOBEC protein averaged 14.3% and 95% for HIV-GFP and
ence how the resulting uracil lesions are processed. AtMLV-GFP, respectively.
either level, pre- or post-deamination, such influences(C) APOBEC3F and APOBEC3G exert their antiretroviral activities
alone could explain the apparent differential dinucleo-independently; coexpression of the two proteins resulted in an addi-
tive drop in the relative level of infectivity. The values shown repre- tide preferences of APOBEC3F and APOBEC3G. Alter-
sent the mean from two independent experiments. Viruses produced natively, the 5-GA (minus-strand TC) dinucleotide pref-
in the presence of the control vector averaged an infectivity of erence of APOBEC3F could be an intrinsic property, as
17.1%. appears to be the case for its DNA deaminase homologs
APOBEC3G and AID [2, 6, 9, 14–17]. To begin to address
whether the propensity for retroviral minus-strand 5-
tions at 29/37 sites observed previously with an MLV- TC is intrinsic to APOBEC3F, we asked whether its ex-
based retrovirus (Figure 2A, underlined guanines; [2]). pression in E. coli would yield a mutator phenotype.
However, despite the high number of APOBEC3G-muta- We used an E. coli mutation assay that employs the
ble sites in the GFP substrate, APOBEC3F triggered G→ drug rifampicin to select for base substitution mutations
A transitions at 35 unique positions. APOBEC3F also in the rpoB (RNA polymerase B) gene (e.g., [14, 17]).
caused G → A hypermutation of MLV-GFP (data not rpoB is essential and therefore only tolerates a limited
shown). These results are best explained by APOBEC3F number of mutations. APOBEC3F expression in E. coli
caused a 4-fold increase in the frequency of mutation tofunctioning to deaminate minus-strand cytosine resi-
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Figure 2. APOBEC3F Triggers RetroviralG→A
Hypermutation
(A) Base substitution mutations in HIV-GFP
produced in the presence of APOBEC3F
(red), APOBEC3G (green), APOBEC3F plus
APOBEC3G (purple), or a vector control
(open). Mutations from the GFP gene consen-
sus base to A, C, G, and T are depicted by
circles, squares, triangles, and diamonds, re-
spectively. G → A transitions are indicated
above, and all other base substitutions are
indicated below, the 747 bp GFP consensus
sequence. One green and five purple G → A
transitions occurred at the 10 position (not
shown). The GFP gene consensus sequence
is numbered beginning at the first coding ad-
enine and differs at two positions from the
consensus reported previously (A69  G and
CC720  AA in MLV-GFP [2]).
(B) Profiles summarizing the types of base
substitution mutations observed in HIV-GFP.
The total number of bases sequenced and
the overall percentages of G → A transitions
are indicated below each profile.
(C) Pie graphs illustrating the proportion of
HIV-GFP sequences that contained the indi-
cated number of mutations. The total number
of sequences analyzed is in the center of each
graph.
rifampicin resistance (Figure 3A), whereas APOBEC3G these sites. At 4/5 of these positions, the cytosines were
preceded by thymines, resulting in a dinucleotide prefer-triggered a 6-fold increase [17]. We sequenced the rpoB
gene of independent rifampicin-resistant mutants and ence similar to that observed in HIV-GFP (Figure 2 and
below). Thus, the observed retroviral hypermutation pat-found a slight increase in the overall level of C/G →
T/A transitions attributable to APOBEC3F (Figure 3B). terns are likely directly attributable to APOBEC3F.
The near-identical N termini of APOBEC3F and APO-However, these mutations were confined to a smaller
number of sites, predominantly C1535, G1546, C1576, C1592, BEC3G suggested that APOBEC3F might also be sus-
ceptible to HIV-1 Vif (virion infectivity factor), which tar-and C1721, which totaled 81.7% (76/93) (boxed in Figure
3C). Cells expressing a control plasmid yielded a sub- gets APOBEC3G for proteasomal destruction prior to
virion incorporation [7, 18–22]. Vif was shown to interactstantially lower transition frequency of 51.2% (43/84) at
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Figure 3. The Distinct 5-GA Dinucleotide (5-TC) Preference of
Figure 4. APOBEC3F Is More Resilient to HIV-1 Vif Than APOBEC3GAPOBEC3F Is Also Apparent in an E. coli-Based Mutation Assay
(A) A representative experiment in which Vif expression restored the(A) Expression of APOBEC3F in uracil DNA glycosylase-deficient
infectivity of HIV-GFP produced in the presence of APOBEC3G butE. coli resulted in a 4- to 5-fold increase in the median frequency
failed to fully restore the infectivity of viruses produced in the pres-of mutation to rifampicin resistance. Mutation assays were per-
ence of APOBEC3F. Each dot represents one cell. See Figure S3formed as described previously [17].
for additional data.(B) A summary of the types of base substitution mutations found in
(B) Titrated expression of HIV-1 Vif restores the infectivity of HIV-the rpoB gene of E. coli expressing APOBEC3F or a vector control.
GFP produced in the presence of APOBEC3G but not that producedThe percentages of C/G → T/A transition mutations and the total
in the presence of APOBEC3F. A 50% lethal dose of APOBEC3Gnumbers of mutants analyzed are shown.
or APOBEC3F or a 25:25 mix of each, together with the amounts(C) Base substitution mutations in the rpoB gene of E. coli express-
of Vif indicated, was present during viral production. The averageing APOBEC3F (above) or a vector control (below). The consensus
number of fluorescing cells resulting from infection by viruses pro-sequence is numbered from the first coding adenine. APOBEC3G
duced with the control constructs was 4.1%.almost exclusively prefers C1691 (highlighted; [17]).
produced in the presence of APOBEC3F was recoveredwith a fragment of APOBEC3G comprising residues 54–
partially by HIV-1 Vif expression and plateaued despite124 [18], with nearby Asp128 also proving critical ([23–26];
further increases in Vif levels (Figure 4B). In contrast,Figure S1). We therefore monitored the infectivity of HIV-
viruses produced with a similar LD of APOBEC3G recov-GFP produced in the presence of Vif or a Vif control,
ered fully. Restoration was predictably intermediate fortogether with APOBEC3F, APOBEC3G, APOBEC3F plus
viruses produced with an LD25 of both APOBEC3F andAPOBEC3G, or a vector control. As reported previously,
APOBEC3G. We noted also that Vif alone repeatedlyVif was capable of restoring the infectivity of viruses
enhanced the infectivity of HIV-GFP in the absence ofproduced in the presence of APOBEC3G (Figures 4A
any APOBEC protein. These experiments indicated thatand S3; [7, 18–22]). In contrast, viruses produced in the
APOBEC3F is partially resistant to HIV-1 Vif, a conclu-presence of APOBEC3F recovered only partially. Viruses
sion that was not reached by two recent studies [27, 28].produced in the presence of both APOBEC3F and APO-
However, a possible molecular explanation consistentBEC3G showed intermediate levels of infectivity re-
with our observations is that the positively chargedcovery.
Arg128 in APOBEC3F (Pro129 in APOBEC3G) likely neutral-To address whether this recovery differential might
izes Glu127 and therefore partially shields the protein frombe related to absolute levels of antiretroviral activity
Vif-mediated degradation. Furthermore, this is consis-provided by these proteins, HIV-GFP was produced in
tent with the fact that Wiegand and colleagues were ablethe presence of an LD50 of APOBEC3F or APOBEC3G
to coimmunoprecipitate more Vif with epitope-taggedor an LD25 of both, together with an increasing amount
of Vif or Vif control. Again, the infectivity of HIV-GFP APOBEC3G than with similarly tagged APOBEC3F [27].
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All of the aforementioned data pointed toward APO-
BEC3F having an important role in restricting HIV-1 in-
fection in vivo. A prediction of this hypothesis is that
some HIV-1 sequences should bear the 5-GA hypermu-
tation signature of APOBEC3F. To address this, we ex-
amined HIV-1 sequence data derived from infected indi-
viduals (Table S1; [11, 29–32]). First, we compared the
abundance of dinucleotides containing retroviral G→ A
hypermutations. As described above, APOBEC3F and
APOBEC3G trigger G→A transition mutations in distinct
dinucleotide contexts, 5-GA (70%) and -GG (87%), re-
spectively (Figure 5A). The preferred dinucleotide of
APOBEC3G agreed well with the value of 82% 5-GG
observed previously with MLV-GFP [2]. Moreover, repli-
cation-competent (Vif-deficient) HIV-1 produced in the
presence of APOBEC3G has shown a similar strong 5-
GG preference [3, 4, 7, 8, 33]. These preferences were
clearly dominant and occurred at the expense of other
bases.
Hypermutated HIV-1 sequences from infected individ-
uals also showed strong 5-GA and -GG dinucleotide
biases with GA more prevalent (Figure 5A). In particular,
Janini and colleagues examined more than 65,000 bp
of HIV-1 protease gene DNA sequences from peripheral
blood mononuclear cells (PBMCs) of 53 HIV-positive
individuals. Forty-three out of 53 patients yielded hyper-
mutated retroviral DNA sequences, and 5-GA was ob-
served nearly twice as often as 5-GG. Although the
latter was clearly apparent, 5-GA even proved dominant
in all individual hypermutated sequences [10]. In the
other studies noted here as well as in additional reports
not dealing solely with HIV-1, the skewing of retroviral
hypermutations occurred invariably toward 5-GA or
-GG and often toward both ([11, 29–32]; also see [34]
and references therein).
These large mutation datasets enabled us to ask
whether the hypermutation signatures of APOBEC3F
and APOBEC3G extended beyond the plus-one position
of the retroviral genomic strand. We focused this analy-
sis on the retroviral minus strand, considered six bases
up- and downstream of the C → T transition site, and
analyzed the 5-TC and -CC hypermutations separately.
A comparison of the sequences flanking all of the
5-TC→ -TT transition sites observed in HIV-GFP in the
presence of APOBEC3F (Figure 2A), with those derived
from patient PBMCs [10, 30], revealed a clear preference
for thymines at positions 2 and 4 (boxed in Figure
5B). This result is particularly striking for the GFP sub-
Figure 5. Retroviral Hypermutation Consensus Sequences and strate embedded within the HIV-based backbone be-
APOBEC Expression Profiles cause it contains only 24% thymine, whereas the minus
(A) Histograms depicting the percentages of retroviral plus-strand strand of HIV-1 is on average 36%–38% thymine-rich
dinucleotides that were hypermutated. Data were derived from Fig- (37.7% in the 297 bp interval examined by Janini and
ure 2 for HIV-GFP (A3F and A3G, first two column sets), from our colleagues [10]). An adenine was preferred at the 1
previous study with MLV-GFP (A3G, third column set; [2]), and from
position in HIV-GFP, with 9/13 of the TCA trinucleotidesanalyses of clinical HIV-1 isolates ( [10, 29–31]; see Table S1). Muta-
tions occurring at GA, GG, and GY dinucleotide contexts are indi-
cated by solid, open, and gray bars, respectively. The number of
sequences analyzed is indicated.
(B) A comparison of the extended local sequence preferences ob- in [A]). See the text for additional details.
served in the minus strand of HIV-GFP produced in the presence (C) Coordinated expression of APOBEC3F and APOBEC3G. North-
of APOBEC3F or APOBEC3G, MLV-GFP produced in the presence ern blot analyses of APOBEC3F, APOBEC3G, and -actin mRNA in
of APOBEC3G, and HIV-1 sequences from patients [10, 30]. The the human tissues indicated. A quantification of the relative hybrid-
preferred dinucleotides involved in hypermutation are highlighted. ization intensities for APOBEC3F (squares) and APOBEC3G (dia-
Additional significant similarities are boxed. Only datasets with more monds) is shown below. See the text and Experimental Procedures
than 100 G → A transitions were considered (these are asterisked for details.
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mutated at least once (averaging 4.7 C → T transitions in retroviral hypermutation frequency (Figures 1, 2, and
S2). This apparent paradox has led us to propose thatper site), and thymine was the next most preferred base
at this position, with 7/8 TCT trinucleotides mutated (3.0 retroviral restriction is at least a two-step process, in
which APOBEC proteins are independently able to incor-C → T transitions per site). The latter also agreed with
the 1 preference observed in patient-derived HIV-1 porate into the virion but are then both cooperatively
and independently able to deaminate C→ U in nascentsequences [10, 30]. These similarities indicated that
APOBEC3F preferred an A or a T at the 1 position retroviral cDNA. Lethal retroviral restriction finalizes this
seemingly paradoxical additive decrease in infectivity.(boxed in Figure 5B). For APOBEC3G, apart from the
prominent 5-CC dinucleotide, a pyrimidine (Y) was Hetero-multimerization at the level of DNA deamination
may then account for the unexpectedly high hypermuta-clearly preferred at the –2 position in hypermutated HIV-
GFP, in MLV-GFP, and in HIV-1 derived from patient tion frequencies. Indeed, Wiegand and colleagues re-
cently showed that APOBEC3F and APOBEC3G couldPBMCs (boxed in Figure 5B; [2]). For all of the datasets,
we additionally noted that a guanine at the 1 position interact [27]. However, our data suggest that the APO-
BEC-APOBEC interaction may not be functionally signif-was strongly disfavored. Thus, the consensus se-
quences for cytosine deamination by APOBEC3F and icant prior to the cytosine deamination step. Such a
two-step mechanism is likely to confer a host advantageAPOBEC3G were 5-TTCWNNT-3 and 5-YCCH-3, re-
spectively (Figure 5B; W  A or T; Y  C or T; and H  because the virus may be forced to reproduce in the
presence of at least two APOBEC proteins, each ofA, C, or T). These extended local preferences were fully
consistent with roles for both APOBEC3F and APO- which may have differential propensities for incorporat-
ing into the virion, resisting Vif, and/or deaminating ret-BEC3G in HIV-1 restriction.
A second prediction of the hypothesis that APOBEC3F roviral nucleic acid.
is active on HIV-1 cDNA is that it should be expressed
Supplemental Datain tissues where HIV-1 resides. Indeed, a 411 bp probe
Supplemental Data are available with this article online at http://specific to the 3 end of the APOBEC3F cDNA hybridized
current-biology.com/cgi/content/full/14/15/1385/DC1/.not only to mRNA isolated from peripheral blood leuko-
cytes but also to a variety of other tissues (Figure 5C).
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